Your browser doesn't support javascript.
loading
The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.
Cuyàs, Elisabet; Buxó, Maria; Ferri Iglesias, Maria José; Verdura, Sara; Pernas, Sonia; Dorca, Joan; Álvarez, Isabel; Martínez, Susana; Pérez-Garcia, Jose Manuel; Batista-López, Norberto; Rodríguez-Sánchez, César A; Amillano, Kepa; Domínguez, Severina; Luque, Maria; Morilla, Idoia; Stradella, Agostina; Viñas, Gemma; Cortés, Javier; Joven, Jorge; Brunet, Joan; López-Bonet, Eugeni; Garcia, Margarita; Saidani, Samiha; Queralt Moles, Xavier; Martin-Castillo, Begoña; Menendez, Javier A.
Afiliação
  • Cuyàs E; Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.
  • Buxó M; Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
  • Ferri Iglesias MJ; Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
  • Verdura S; Laboratori Clínic Territorial, Parque Hospitalario Martí i Julià, Salt, Spain.
  • Pernas S; Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.
  • Dorca J; Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
  • Álvarez I; Breast Unit, Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Martínez S; Medical Oncology, Catalan Institute of Oncology, Girona, Spain.
  • Pérez-Garcia JM; Medical Oncology Service, Hospital Universitario Donostia, Donostia-San Sebastián, Spain.
  • Batista-López N; Biodonostia Health Research Institute, Donostia-San Sebastián, Spain.
  • Rodríguez-Sánchez CA; Medical Oncology Department, Hospital de Mataró, Mataró, Barcelona, Spain.
  • Amillano K; Hospital Quirón, IOB Institute of Oncology, Barcelona, Spain.
  • Domínguez S; Medical Oncology Service, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain.
  • Luque M; Medical Oncology Service, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Morilla I; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
  • Stradella A; Medical Oncology, Hospital Universitari Sant Joan, Reus, Spain.
  • Viñas G; Medical Oncology Service, Hospital Universitario Araba, Vitoria-Gasteiz, Spain.
  • Cortés J; Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Joven J; Breast Unit, Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Brunet J; Breast Unit, Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • López-Bonet E; Medical Oncology, Catalan Institute of Oncology, Girona, Spain.
  • Garcia M; Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain.
  • Saidani S; Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain.
  • Queralt Moles X; Medical Oncology, Catalan Institute of Oncology, Girona, Spain.
  • Martin-Castillo B; Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
  • Menendez JA; Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
Front Oncol ; 9: 193, 2019.
Article em En | MEDLINE | ID: mdl-30984619
ABSTRACT

Background:

The minor allele (C) of the single-nucleotide polymorphism (SNP) rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabetes. We herein investigated whether the same SNP would predict clinical response to neoadjuvant metformin in women with early breast cancer (BC).

Methods:

DNA was collected from 79 patients included in the intention-to-treat population of the METTEN study, a phase 2 clinical trial of HER2-positive BC patients randomized to receive either metformin combined with anthracycline/taxane-based chemotherapy and trastuzumab or equivalent regimen without metformin, before surgery. SNP rs11212617 genotyping was assessed using allelic discrimination by quantitative polymerase chain reaction.

Results:

Logistic regression analyses revealed a significant relationship between the rs11212617 genotype and the ability of treatment arms to achieve a pathological complete response (pCR) in patients (odds ratio [OR]genotype×arm = 10.33, 95% confidence interval [CI] 1.29-82.89, p = 0.028). In the metformin-containing arm, patients bearing the rs11212617 C allele had a significantly higher probability of pCR (OR A/C,C/C = 7.94, 95%CI 1.60-39.42, p = 0.011). Conversely, no association was found between rs11212617 and clinical response in the reference arm (OR A/C,C/C = 0.77, 95%CI 0.20-2.92, p = 0.700). After controlling for tumor size and hormone receptor status, the rs11212617 C allele remained a significant predictor of pCR solely in the metformin-containing arm.

Conclusions:

If reproducible, the rs11212617 C allele might warrant consideration as a predictive clinical biomarker to inform the personalized use of metformin in BC patients. Trial Registration EU Clinical Trials Register, EudraCT number 2011-000490-30. Registered 28 February 2011, https//www.clinicaltrialsregister.eu/ctr-search/trial/2011-000490-30/ES.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article